News Kancera AB

Equities

KAN

SE0015658570

Market Closed - Nasdaq Stockholm Other stock markets 11:29:47 2024-04-26 am EDT			5-day change	1st Jan Change
1.412 ^SEK	-2.49%		-4.98%	-68.93%

Feb. 23	Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 23	Kancera AB Signs A License Agreement with the University of Newcastle	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kancera announces the outcome of the company's rights issue	Mar. 20	AQ
Kancera publishes prospectus in connection with the company’s rights issue	Mar. 01	AQ
Kancera resolves on a rights issue of approximately SEK 121.9 million	Feb. 23	AQ
Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851	Feb. 23	AQ
Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study	Feb. 23	AQ
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Kancera AB Signs A License Agreement with the University of Newcastle	Feb. 23	CI
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Kancera presents the statistical analysis of top line data from the FRACTAL study	Feb. 06	AQ
Kancera AB Presents the statistical Analysis of Top Line Data from the FRACTAL Study	Feb. 06	CI
Kancera reports positive top line results from the FRACTAL study	Dec. 20	AQ
Kancera AB Reports Positive Top Line Results from the FRACTAL Study	Dec. 20	CI
Kancera provides operational update in connection with release of financial interim report for third quarter 2023	Nov. 17	AQ
Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851	Nov. 17	AQ
Kancera AB Provides Operational Update Regarding Fractalkine Block Blockers KAN567 and KAND145	Nov. 17	CI
Kancera AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI
Kancera reports that the phase I study of KAND145 has received regulatory approval	23-10-23	AQ
Kancera AB Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145	23-10-23	CI
Kancera announces that the FRACTAL top line results are expected to be presented by the end of December 2023	23-10-13	AQ
Kancera Names Successor to Outgoing Chief Medical Officer	23-09-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kancera AB

Equities

KAN

SE0015658570

Summary

Filters